CoEnzyme Q10: New approach in the treatment of corneal damage and glaucoma
Dear ESCRS Attendees,

I am pleased to introduce VISUfarma to you. We are a pan-European eye health company with a commercial presence in all major European countries. The company was created in 2016 and is the result of the acquisition of the Italian VISUfarma and the French-European Nicox. The combined VISUfarma already has a strong portfolio of established products in eye health.

We are pleased to introduce two innovative products featuring CoEnzyme Q10. One is VisuXL, a novel treatment which accelerates corneal healing after surgery and damage caused by dry eye disease. The other is CoQun®, a topical complementary treatment to antihypertensive glaucoma therapy.

We look forward to welcoming you at our lunch symposium.

Tom van Haarlem, MD, CEO VISUfarma

---

Dear Colleagues,

We are looking forward to welcoming you to the CoEnzyme Q10 Symposium. It will be an outstanding opportunity to discuss new developments in ophthalmology.

**Coenzyme Q10 (CoQ10)** is an endogenous molecule present in the mitochondria where it serves as an electron transporter for ATP production. CoQ10 is also an inhibitor of the apoptotic signal transduction and an effective antioxidant.

**Cross-linked HA and CoQ10** are two innovations, newly combined, which have demonstrated accelerated healing of the ocular surface, and also of the sub-basal layer of the cornea. In glaucoma, **Coenzyme Q10**, administered as eye drops has growing evidence to prevent RGC damage and apoptosis, and to have beneficial effects on retinal function.

The Symposium will provide a great opportunity to familiarize yourself with these new applications of CoQ10.

Prof. Leopold Schmetterer, Scientific Chair of the Symposium

---

**Programme**

**Chairman**

Prof. Leopold Schmetterer, Professor of Ophthalmology, Singapore Eye Research Institute, Nanyang Technological University, Singapore; Medical University Vienna, Austria

**CoQ10 and mitochondrial function: what is their role in ocular diseases?**

Dr. Sajjad Ahmad, Consultant Ophthalmic Surgeon, Moorfields Eye Hospital; Senior Clinical Lecturer, UCL Institute of Ophthalmology, London, UK

**Cross-Linked HA and CoQ10: their impact in dry eye disease & ocular surface damage**

Prof. Pasquale Aragona, Full Professor and Chairman of Ophthalmology, Eye Clinic, Dept. of Biomedical Sciences, University of Messina, Italy

**CoQ10 and surgery: its benefits in corneal regeneration**

Prof. José Manuel Benítez del Castillo Sánchez, Professor of Ophthalmology and Chairman, Hospital Clínico San Carlos, Madrid; Spain; Professor of Ophthalmology, University Complutense of Madrid

**CoQ10 and glaucoma: evidence and effects in the preservation of Retinal Ganglion Cells**

Prof. Francesca Cordeiro, Professor of Ophthalmology, Imperial College London; Professor of Glaucoma and Retinal Neurodegeneration, UCL, United Kingdom

---

**CoEnzyme Q10: New approach in the treatment of corneal damage and glaucoma**

**Monday October 9th, 13.00 - 14.00- Room 4.2**